SCHEMBL17769661

SCHEMBL17769661

CCNC(=O)N1c2nc(-c3cccc(C(F)(F)F)c3)ncc2N2CC[C@H]1C2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 1/20 0.39
▸ ALDH1A1 P00352 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ CYP2C19 P33261 1/20 0.39
▸ KCNH2 Q12809 1/20 0.38
▸ ACACB O00763 1/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ POLB P06746 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ CPT2 P23786 1/20 0.38
▸ CPT1A P50416 1/20 0.38
▸ CKS1B P61024 1/20 0.37
▸ SKP1 P63208 1/20 0.37
▸ SKP2 Q13309 1/20 0.37
▸ PAK1 Q13153 1/20 0.37
▸ KCNJ6 P48051 1/20 0.37
▸ KCNJ5 P48544 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17769444 0.88 DPP4 (0.41) IRAK4ALDH1A1KDM4ECYP2C9HPGD
SCHEMBL17778466 0.88 DPP4 (0.41) IRAK4ALDH1A1KDM4ECYP2C9HPGD
SCHEMBL20550479 0.88 ALDH1A1 (0.42) IRAK4ALDH1A1KDM4ECYP2C9HPGD
SCHEMBL20550603 0.86 ALDH1A1 (0.47) IRAK4ALDH1A1KDM4ECYP2C9HPGD
SCHEMBL17778371 0.86 ALDH1A1 (0.45) IRAK4ALDH1A1KDM4ECYP2C9HPGD
SCHEMBL19689756 0.86 KMT2A (0.41) ALDH1A1ACACBKMT2AMEN1TSHR
Hydrochloric Acid SCHEMBL19689854 0.85 KMT2A (0.40) ALDH1A1ACACBKMT2AMEN1TSHR
SCHEMBL17778498 0.84 PHGDH (0.41) ALDH1A1KDM4ECYP2C9HPGDCYP2C19
SCHEMBL17769507 0.83 ALDH1A1 (0.43) ALDH1A1KDM4ECYP2C9CYP2C19KCNH2
SCHEMBL17769468 0.83 ALDH1A1 (0.43) ALDH1A1KDM4ECYP2C9CYP2C19KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180319810-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2018-11-08 — — US disclosed
EP-3220918-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2017-09-27 — — EP disclosed
WO-2016079712-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-05-26 — — WO disclosed
WO-2016079712-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-05-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180319810-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 IRAK4 2915/4885ALDH1A1 1067/4885KDM4E 1291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback